OTCPicks.com

FEATURED COMPANY

VSURANCE INC (OTCBB: VSUR)

Detailed Quote: http://www.otcpicks.com/quotes/VSUR.php

Company Profile: http://www.otcpicks.com/vsurance/vsurance.htm

Vsurance is a leading provider of pet health insurance and other pet health-related services in the United States. Programs include its Get HIP™ Pet Health Insurance for Pets program, the most comprehensive full-coverage pet health insurance plan in the industry. Vsurance provides pet and horse resource centers through the Internet including VetpetMD™, Spot the Pet™, and Purrfect Pet Club™. Programs include life, liability, and health insurance for pets, horses, and other companion animals.

VSUR News:

November 9 - Vsurance, Inc. Expands Presence in Pet Health Insurance Marketplace Doubles Licensed Insurance Representatives in 17 States

Vsurance, Inc. (OTCBB: VSUR), a leading provider of pet health insurance, announced that as part of its ongoing commitment to increase public awareness of the importance of pet health insurance, and to increase its revenues, the Company has more than doubled its number of licensed insurance representatives to 94, in 17 States within the past week.

The news complements a previous announcement earlier this week in which Vsurance stated that the company had increased its number of its licensed insurance agents to 40.

Russell Smith, CEO of Vsurance, Inc. stated: “Earlier this week we announced that we appointed 40 licensed insurance agents to meet the growing demand for our pet health insurance products. It has become increasingly apparent that the positive public response and acceptance of our insurance products warranted appointing additional agents in various states around the country. I am very pleased to announce that we have more than doubled the number of our licensed insurance representatives. This is a true testament that our pet health insurance products are in high demand. We will continue to increase our personnel as our innovative products gain greater awareness throughout the marketplace.”

FEATURED COMPANY

UNIVERSAL ENERGY CORP (OTCBB: UVSE)

Detailed Quote: http://www.otcpicks.com/quotes/UVSE.php

Company Profile:
http://www.otcpicks.com/universal-energy/universal-energy.htm

Universal Energy Corp. is an energy company engaged in the acquisition and development of crude oil and natural gas leases in the United States and Canada. We pursue oil and gas prospects in partnership with oil and gas companies with exploration, development and production expertise. Our prospect areas consist of lands in Alberta, Canada, Louisiana and Texas. Visit www.universalenergycorp.info for more details.

UVSE News:

November 8 - Universal Energy Corp. to Begin Oil Production from Amberjack Prospect this Month

Universal Energy Corp. (OTCBB: UVSE) recently offered an update on the three recent successful drill programs at its Amberjack, Caviar #1, and Lake Campo prospects. "Completing these three wells and getting them into production is our top priority and it's occurring as we speak," stated Billy Raley CEO of Universal Energy Corp.

"Receiving revenue from the Amberjack well is exciting for the company and its stockholders; especially with oil continuing its climb to $100 per barrel," commented Dyron Watford, CFO of Universal Energy Corp. Watford continued "With each day that passes, the company is turning its drilling success in its last three drills into financial success for its stockholders."

Continuing its model of growth through the drill bit, Universal Energy Corp. is currently drilling two additional wells in southern Louisiana, East OMG and West Rosedale.

About the East OMG Prospect

The East OMG 3-D prospect is located in Cameron Parish, Louisiana. Wells adjacent to the prospect have produced outstanding returns such as Chalkley Miogyp field and S. Lake Arthur, which have cumulative production of 500 billion cubic feet equivalent ("BCFE") and 800 billion cubic feet, respectively. Production from the adjacent wells listed above is from the same Upper Miogyp sandstones that are the main objective of the East OMG Prospect. The combined reserve potential of the four principal objective sandstones that comprise the East OMG prospect is estimated to be greater than 59 BCFE.

About the W. Rosedale Prospect

The W. Rosedale 3-D prospect located in Iberville Parish, Louisiana. Numerous area fields, such as Happytown, Rosedale, Klondike, and Grosse Tete, have produced significant oil and gas from the Oligocene age objective sand section. Risk reduction for this prospect is from log and core shows in seven of the eight objective sands. The reserve potential for this prospect is 3.5 BCF and 910,000 BBLS.

FEATURED COMPANY

SPONGETECH DELIVERY SYSTEMS (OTCBB: SPNG)

Detailed Quote: http://www.otcpicks.com/quotes/SPNG.php

Company Profile: http://www.otcpicks.com/spongetech/spongetech.htm

SpongeTech Delivery Systems is a development stage company which designs, produces, markets and distributes cleaning products for vehicular use utilizing patented technology relating to sponges containing hydrophilic (liquid absorbing) foam polyurethane matrices. The Company's sponges are specially configured with an outer contact layer and an inner matrix, which is loaded with specially formulated soaps and wax that are released when the sponge is applied to a surface with minimal pressure. The Company's products are currently designed specifically for vehicular cleaning use. However, the Company is exploring the possibility of using its patented technology for the development of sponges for other uses, including for use with anti-bacterial, bath and kitchen soaps for household uses, as well as for use as a children's bath foam sponge.

SPNG News:

November 5 - Successful APEX/SEMA Auto Show for SpongeTech Delivery Systems in Las Vegas

SpongeTech Had Numerous Domestic and International Retailers Showing a High Interest in Products

SpongeTech Delivery Systems, Inc. (OTCBB: SPNG) exhibited its SpongeTech Delivery Systems Car Wash & Wax products at the APEX/ SEMA (Specialty Equipment Market Association) show which was held in Las Vegas this past week. The APEX/SEMA Auto Show in Las Vegas is truly unique among car shows. For one, it's not open to the public. The APEX/ SEMA show is for members of the trade only, so unless you build, sell or are in some way associated with the aftermarket auto parts and accessories industry you can't go. That restriction doesn't limit the attendance, however, as the SEMA auto show floor is as crowded as any of the other big city auto shows.

SpongeTech Delivery System's CFO Steven Moskowitz commented, "We had a fantastic APEX/SEMA show this past week. This is one of the best automotive industry shows we have attended to date and the contacts we made at the show were excellent. We had automotive resellers and retailers from all over the world visit us at our booth." Mr. Moskowitz continued, "While we cannot divulge contact names, suffice to say, that we enjoyed very high traffic by numerous domestic and international big-box retailers, several well known automotive supply retailers, prospective automotive product distributors in a large number of international markets, and very well known and highly respected automotive product suppliers interested in private labeling SpongeTech Car Care products with their own trade brand. If we can close deals with just 5% of the contacts that visited us at the show we will significantly grow our business in 2008 beyond the orders currently on our books. The great thing about the APEX/SEMA show was that there were no 'Tire Kickers.' All of the attendees were industry related resellers, distributors, retailers and rep firms, so the vast majority of the leads we gathered were legitimate and prospective future SpongeTech customers."

For more information, contact Investor Relations at 1-877-SPONGE T or visit the company website at www.spongetech.com.

FEATURED COMPANY

SIGNATURE DEVICES (OTC: SDVI)
"Up 9.89% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SDVI.php

Company Profile:
http://www.otcpicks.com/signature-devices/signature-devices.htm

Signature Devices, Inc. engages in the development, manufacture, and sale of information technology products in the United States. The company creates, develops, and publishes 3-D interactive games for consoles and personal computers. It also publishes software for video games and commercial products. The company publishes games for consoles, such as GBA, XBox360, and Playstation. In addition, the company provides consulting for information technology, including computer systems, software, and electronic products. It offers a platform for hardware, embedded systems development, and image generation technology, which can be used in films, videogames, and the military. Further, the company develops customized 3D identities, including lighting, shading, artificial intelligence, and animation systems. Signature Devices was founded in 2002 and is headquartered in Redwood City, California.

SDVI News:

November 9 - MoneyTV Interviews Signature Devices CEO Kenneth Hurley

MoneyTV (www.moneytv.net), the nationally syndicated television program featuring informative interviews by hosts Donald Baillargeon and Skip Lindeman with company CEOs, will feature Signature Devices, Inc. (OTC: SDVI) CEO Kenneth Hurley.

Hurley spoke of the burgeoning video game industry the company is doing business in, announced new games in beta soon to be released and updated progress towards the company upgrading their stock listing to the Bulletin Board Exchange.

FEATURED COMPANY

ETELCHARGE.COM INC (OTCBB: ETLC)
"Up 5.88% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ETLC.php

View Profile: http://www.otcpicks.com/etelcharge.com/etelcharge.htm

Etelcharge.com (OTCBB: ETLC), the first Web 2.0 online payment system, provides online shoppers the ability to charge approved transactions to their telephone bill. While addressing the concerns online shoppers have about identity fraud and identity theft, the Etelcharge payment option is also a perfect match for the millions of individuals without a credit card, or even a bank account. For more information, go to www.etelcharge.com.

ETLC News:

November 8 - Etelcharge Enters Payment Services Agreement With Elite Force

Company Enters Consumer Electronics Installation and Support Industry With Nationally Expanding Leader and Meets With Senior Management as Netflix, Real Networks, CinemaNow, UniVision and Movielink

Etelcharge.com, Inc. (OTCBB: ETLC), the new online way to pay(TM), today announced that the Company has signed an agreement with Elite Force, of Falls Church, VA, the successor to Tech Force One and one of the top independent providers in the multi-billion dollar PC and consumer electronics installation and support industry.

John Todd, Senior Vice President of Business Development, stated, "I am pleased to report that Etelcharge has signed a payment services agreement with one of the country's top electronics installation and PC repair companies. Elite Force, with 200 locations today and expanding to 1,000 locations in 2008, is similar to Fire Dog and Geek Squad, in that they install high-end multimedia systems and networks in homes, as well as providing the full array of support services for consumer electronics and PCs. Etelcharge members will be able to pay for Elite Force services using their Etelcharge membership. We expect this program to come online for our members in early 2008."

John Todd concurrently announced that during his recent trip to California attending the Digital Hollywood Show, he engaged in substantive talks with a select group of elite players in the digital music and movie downloads space including Netflix, Real Networks (Rhapsody), CinemaNow, UniVision, and Movielink.

"I was able to successfully establish the huge importance of our target customer to their continued growth. Reinforcing to the executive management teams of these companies that Etelcharge not only brings a unique and enticing Web 2.0 payment system but also brings a whole new set of new customers, that is growing by the day, who will be spending new money with them that they are not getting today. The impact to their bottom line garnered exceptional levels of interest," Todd concluded.

STOCKS TO WATCH

DUSA PHARMACEUTICALS (NASD: DUSA)
"Up 6.47% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DUSA.php

DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of actinic keratoses of the face or scalp. Kerastick is a disposable applicator used for the rapid preparation and uniform application of Levulan topical solution in standardized doses. The BLU-U is used without Levulan to treat moderate inflammatory acne vulgaris and general dermatological conditions. The company is also developing Levulan PDT, a Phase II clinical trial product to treat photodamaged skin, moderate to severe acne vulgaris, Barrett's esophagus dysplasia using DUSA endoscopic light delivery system, and oral cavity dysplasia. In addition, the company is developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, and Psoriatec for the treatment of acne vulgaris and acne rosacea, as well as psoriasis; ClindaReach; Meted Shampoo; and Psoriacap. The company was founded in 1991 and is based in Wilmington, Massachusetts.

DUSA News:

November 9 - DUSA Pharmaceuticals Reports Third Quarter 2007 Financial Results and Corporate Highlights

Revenues Total $5.8 Million; Bottom Line Improves 50%; Initial Latin American Orders Shipped; Nicomide(R) Lawsuit Settled; Company Enhances Cash Position

DUSA Pharmaceuticals, Inc. (NASD: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, reported its corporate highlights and financial results for the third quarter ended September 30, 2007.

Total product revenues for the quarter were $5.8 million as compared to $6.1 million for the comparable 2006 period. PDT revenues totaled $3.5 million versus $3.2 million for the comparable 2006 period. The increase in PDT revenues was driven primarily by a 17% increase in U.S. Levulan® Kerastick® revenue. Non-PDT revenues totaled $2.3 million versus $2.8 million for the comparable 2006 period. Non-PDT revenues were primarily driven by the sales of Nicomide® which were adversely impacted by the presence of the River's Edge product, which re-entered the market as a result of the March 7, 2007 dissolution of a preliminary injunction.

Total product revenues for the nine-month period ended September 30, 2007 were $19.3 million as compared to $17.4 million for the comparable 2006 period. PDT revenues totaled $12.1 million versus $10.9 million in the comparable 2006 period. Non-PDT revenues totaled $7.2 million versus $6.5 million in the comparable 2006 period. Non-PDT revenues for 2006 represent the period following our merger with Sirius Laboratories, Inc.®, which occurred on March 10, 2006.

For the three-month and nine-month periods ended September 30, 2007, DUSA's net loss on a GAAP basis was ($1.9) million, or ($0.10) per common share, and ($7.7) million, or ($0.40) per common share, respectively. GAAP net losses for the comparable 2006 periods were ($3.8) million, or ($0.19) per common share, and ($13.1) million, or ($0.77) per common share. On a non-GAAP basis, the Company's net losses for the three-month and nine-month periods ended September 30, 2007 were ($1.4) million, or ($0.07) per common share, and ($6.6) million, or ($0.34) per common share, respectively. Non-GAAP net losses for the comparable 2006 periods were ($2.9) million, or ($0.15) per common share, and ($9.1) million, or ($0.53) per common share. Both the 2007 quarterly GAAP and non-GAAP net losses represent a 50% decrease from the prior year. Investors are encouraged to refer to the "Use of Non-GAAP Financial Measures" section and the accompanying financial table for a reconciliation of GAAP to non-GAAP information.

Third Quarter Highlights:

International Expansion

In late September, the first shipments of Levulan® Kerastick® were released to Argentina and Mexico where it was officially launched through DUSA's marketing and distribution partner for Latin America, Stiefel Laboratories, Inc. In Latin America, Levulan has regulatory approval in Argentina, Chile, Colombia, Mexico, and Brazil (where launch is pending receipt of acceptable pricing approval) with approvals and subsequent product launches in additional markets scheduled to follow shortly.

Product Development

Enrollment continues in DUSA's Phase IIb clinical trial of Levulan® PDT for the treatment of moderate to severe acne. To date, 13 clinical sites have accrued 149 patients.

Subsequent Events:

International Regulatory Approval

On October 3, 2007, the Company announced that the Korea Food and Drug Administration (KFDA) had approved Levulan® Kerastick® for Photodynamic Therapy (PDT) for the treatment of actinic keratoses through its marketing and distribution partner Daewoong Pharmaceutical Co., Ltd and its affiliate, DNC Daewoong Derma & Plastic Surgery Network Company (DNCompany). Having received approval, market launch is expected in the fourth quarter of 2007.

Legal Proceedings

On October 29, 2007, the Company announced that it had entered into a settlement and mutual release agreement to dismiss the lawsuit brought against River's Edge asserting a number of claims arising out of River's Edge's alleged infringement of the U.S. Patent under which DUSA has marketed, distributed and sold Nicomide®. Per the terms of the agreement, River's Edge has made a lump-sum settlement payment to DUSA for damages and will permanently cease the manufacture, distribution and sale of its nicotinamide product, NIC 750. DUSA has licensed to River's Edge four products from the AVAR® line which are non-strategic to DUSA in exchange for a royalty for three years, including a guaranteed minimum royalty.

Cash

On October 30, 2007, the Company announced that it had entered into definitive agreements with certain institutional investors for the private placement of 4,581,043 shares of its common stock at a purchase price of $2.40 per share resulting in gross proceeds to DUSA of $11.0 million. In addition, the Company has granted the investors warrants to purchase an additional 1,145,259 shares of common stock at a strike price of $2.85 per share. The Company will use the proceeds to fund working capital, further advance DUSA's Levulan PDT clinical development programs, and for activities associated with expanding the Company's market presence in the U.S.

Management Comments:

"We are pleased with the progress we are making with our Levulan PDT franchise," stated President and CEO Robert Doman. "Domestic Kerastick revenues are up 23% year-over-year, the product has been launched into Latin America, and approval has been received in Korea with expected product launch in the fourth quarter this year. In addition, enrollment is progressing nicely on our Phase IIb Acne trial."

"We are also pleased to have fully resolved the dispute with River's Edge. This settlement underscores DUSA's commitment to protecting its intellectual property. We look forward to increasing our Nicomide® revenue stream as ordering patterns return to normal levels", Doman continued.

"Lastly, the infusion of cash from the private placement helps us to strengthen our balance sheet and execute on our business plan as we position the Company for continued growth in 2008 and beyond," concluded Doman.

TITAN RESOURCES (OTC: TNRI)
"Up 46.67% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/TNRI.php

TITAN Resources International Inc. is a publicly traded resource exploration company dedicated to the acquisition, exploration and development of small to medium size precious metals properties of exceptional merit in North and South America. For more information, visit www.titan-resource.com.

TNRI News:

November 7 - The Silver Lining

Titan Resources International Inc. (OTC: TNRI) (Frankfurt: 36T1.F) recently updated shareholders on its plans for the Silver Centre Property:

To understand what we are attempting to do with the Silver Centre Property, you have to try to understand some of the fundamentals that drive the demand and supply relationships within the silver markets.

While we cannot address all of the mitigating circumstances and influences that affect the silver market, we can attempt to better educate and inform our existing shareholders, possibly attracting new ones. We have put together a brief overview of some of the main factors to consider when looking at the possibility of investing in silver, and the silver mining industry.

Take into account that overall global demand for silver continues to outpace supply.

The top uses for silver worldwide continue to be Industrial applications and fabrications, jewelry and photography, respectively.

Most of the world's silver production comes as the result of secondary recovery (silver is recovered secondarily, as the result of mining for other primary minerals, usually gold).

Peru is the largest producer of silver in the world, followed closely by Mexico and China. Canada ranks in the top 10 for global silver production.

Most of the world's silver is found in low grade, easily accessible ore. There are relatively few "High Grade" silver deposits, and even fewer silver mines that mine for silver as their primary metal.

And then there is the relationship that exists between silver and gold, and currency fluctuations.

"The question is simple yet potentially vexing to silver investors. Gold has now closed above $800 for the first time since January 17th, 1980. One may naturally ask what the price of silver was at that time and the answer would be $40. When investors demand silver as a dollar hedge, you can't just press a key on your computer and a 1000 oz bar of silver appears out of the ether. No it first has to be discovered, dug out deep from the ground, refined to 99.9% purity and then poured into investment grade bars which are shipped to warehouses. This is obviously not a trivial matter and hence firmly puts a supply bottleneck on silver availability. The result is a faster rising price of silver."

Dennis Wheeler, chief executive of Coeur d'Alene Mines, picked up on an expression much-used in the month and averred that silver and gold prices were heading into a perfect storm, by which he meant something good for silver. "Growing demand is running headlong into dwindling supply, at a time when the dollar is weakening and inflationary worries persist. Some production is coming off line, and the move by Grupo Mexico to close its Taxco silver and lead operation, after failure to resolve a lengthy industrial dispute, will see almost 1 million ounces annually removed from the market."

Jeff Hunter, Titan CEO, said, "We don't sell MP3 players, with a great marketing campaign every year. We're going to build mines; I think that is one of the things investors are starting to appreciate. Based on the historic prolific past production of the SCR property (more than 19 million ounces of silver, over 3 million pounds of cobalt), and the current plan being implemented on the property, we continue to be very optimistic about the possibility of discovering, and ultimately proving up, a significant new ore body. The recent appreciation in the price of silver only serves to cement our resolve in what we are doing."

WELWIND ENERGY INTERNATIONAL (OTCBB: WWEI)
"Up 15.79% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/WWEI.php

Welwind Energy International Corp. is committed to providing the best resource option available for renewable energy, protecting our environment, empowering communities, bolstering local economies and respecting the rights of future generations. Welwind Energy International was founded to build, own and operate wind farms on an international scale. The company's goal is to become a leading provider of clean energy products for the residential, business and governmental consumer.

WWEI News:

November 9 - Welwind Energy International Receives Letter of Interest to Finance the Company's Zhanjiang Windfarm

Welwind Energy International Corp. (OTCBB: WWEI) (the “Company”) announced that it has received a letter of interest from Acterra Group to fund Phase I of the company's Zhanjiang Windfarm project. Phase I consists of 65 turbines at 1.2-1.5 million per turbine. This commitment will be up to, but not limited to, $75 million.

“We are very pleased at obtaining this letter of interest as it is one of the final steps required by the local power authority in obtaining our PPA,” said Mr. Shannon de Delley, Director of Welwind. “Clearly, obtaining financing without further dilution in shareholder stock positions is best for all and financing of this magnitude will propel this company as a major player in the alternative energy market,” he added.

Acterra is quite comfortable that financing of the project will be completed once a PPA is in place along with necessary EPC and other standard requirements. Acterra will assist in this process by providing access to project finance legal counsel in preparing such contracts.

“We have been working and negotiating with several finance groups for our two projects and the various phases of development for each – we are quite pleased in moving forward with Acterra Group,” said Tammy McNabb, CEO of Welwind. “There are multiple steps in obtaining a PPA and we would like to thank our shareholders for their patience and their confidence in management's ability in getting the company to this very exciting point. We anticipate financing and build out of Phase I within the first quarter of 2008.”

ABOUT ACTERRA GROUP

For nearly 50 years the people of the Acterra Group have been providing services and support to energy, natural resource, and sustainability companies. From project inception through completion they assist in all areas.

The staff of the Acterra Group is actively working to support the renewable energy market. They deliver services in a number of different ways, each dependent upon the needs and expertise of the clients.

Acterra brings a complete understanding of all project aspects to the management of renewable energy projects thorough technical understanding, construction capabilities, operational talent as well as the underlying financial and management skills necessary for complex programs and comprehensive projects.

MARSHALL HOLDINGS INTERNATIONAL (OTCBB: MHII)
"Up 10.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MHII.php

Marshall Holdings International, Inc., together with its subsidiaries, engages in the marketing and distribution of nutritional and health products in the United States, Canada, Russia, and Indonesia. It distributes vitamins, nutritional supplements, whole health foods, and skin care products. The company's nutritional/health products comprise Body Gard with Lactoferrin; Femme; Fulvic Factor; Lifetonic; LifeZymePlus; Master Formula powder and capsules; Natural Immunity; New Life Corrective A, B, and C; Superfood powder and capsules; and Vibrant 9 skin care products. It also distributes a line of teas, herbs, minerals, homeopathic remedies, natural cosmetics, skin care, pet care, cold and wellness products, and weight management products. In addition, the company owns an ecommerce platform that facilitates online sales of products through Websites. Marshall Holdings distributes its products through a network of independent distributors to the retail customers. The company, formerly known as Gateway Distributors, Ltd., was founded in 1993 and is based in North Las Vegas, Nevada.

MHII News:

November 9 - Marshall Holdings Announces Two Million Dollar Funding Agreement

Marshall Holdings International, Inc. (OTCBB: MHII) announced that it has come to terms with CAMOFI Master LDC (“Secured Party”), D. L. Claire Capital, Inc., a Delaware corporation with its principal business address at 60 East 42nd Street, Suite 3405, New York, New York 10165 to attain funding for the continued expansion of it product line and sales. The funding is for up to two million dollars which will be in phases based on performance. The initial phase has been approved and processed for $650,000.

Rick Bailey, President / CEO, said, “This allows us to expand our business both in the USA and globally. We have signed contracts to introduce our products to several countries and signed agreements to feature our products on global websites. It will definitely strengthen our position in our industry and allow growth to take place. The Company also has extended its contract agreement with PT. Mahakam Beta Farma for an additional three years and will triple our sales of our product Body Gard. In addition, PT. Mahakam Farma has completed Clinical trials on Body Gard.”

CANAM ENERGY (OTC: CNGJ)
"Up 10.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CNGJ.php

Canam Energy Inc. is a rapidly emerging mineral exploration company with a corporate mandate to define and explore mineral properties worldwide. The company will acquire highly prospective properties, predominately uranium, that offer the opportunity for expansion and development. Canam Energy Inc. currently has properties in the Sudbury Basin in Ontario and Mongolia.

CNGJ News:

November 8 - Canam Energy Inc. (CNGJ) Announces Appointment of Senior Geophysical and Mine Technician

Canam Energy Inc. (OTC: CNGJ), "The Company", an exploration company aggressively pursuing mineral properties in the Uranium industry announced that it has added to its advisory board Mr. Murray Gauthier. Mr. Gauthier comes with an extensive background in mining and exploration, including Senior Geological Technician for Cameco Corporation, the largest Uranium producer in the world, on their U/G Uranium Mine from 1996- 2002. http://www.cameco.com

Mr. Gauthier will assist in the company's corporate goals of acquiring new properties as well as exploration of current and any future land holdings.

An extensive exploration program for the companies holdings including geological and radio-metric surveying and ultimately drilling is planned for the 2007-2008 season.

The company is confident that Quebec represents a promising opportunity for uranium exploration and its properties are located in a prolific area with many operational camps and an operating uranium mine in the immediate vicinity. The increased commodity price for uranium coupled with the growing global demand also fits with the company's strategy of mobility and diversification.

CRITICAL THERAPEUTICS (NASD: CRTX)
"Up 4.17% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CTRX.php

Critical Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products to treat respiratory, inflammatory, and critical care diseases linked to the body's inflammatory response. It markets ZYFLO, a tablet formulation of zileuton, which is used for the prevention and chronic treatment of asthma in adults and children 12 years of age or older in the United States. The company is also developing a controlled-release formulation of zileuton, or zileuton CR, a tablet designed to be taken twice daily, for the prevention and chronic treatment of asthma; and zileuton injection, which is in Phase II clinical trials for use in emergency room or urgent care centers for patients who suffer acute exacerbations of asthma. zileuton also has therapeutic benefits in treating various diseases and conditions, including acute asthma exacerbations and chronic obstructive pulmonary disease. In addition, Critical Therapeutics has a preclinical program, alpha-7, for oral anti-cytokine therapy for acute and chronic inflammatory diseases, such as asthma and rheumatoid arthritis. It has collaboration with MedImmune, Inc. on preclinical development of monoclonal antibodies directed toward a cytokine, called HMGB1, or high mobility group box protein 1, for the development of products to treat diseases mediated by the inflammatory response; CyDex, Inc. for the clinical development and marketing of the injectable formulation of its asthma drug Zileuton; and Beckman Coulter, Inc. on the development of a diagnostic directed toward measuring HMGB1 in the bloodstream. The company was founded in 2000 as Medicept, Inc. and changed its name to Critical Therapeutics, Inc. in 2001. Critical Therapeutics is based in Lexington, Massachusetts.

CRTX News:

November 8 - Critical Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2007

Company Initiates Review of Business Strategy and Strategic Alternatives

Critical Therapeutics, Inc. (NASD: CRTX) reported financial results for the three and nine months ended September 30, 2007. The Company also announced that it is currently considering potential changes to its business strategy and has engaged an investment bank to advise it on potential strategic alternatives.

“We have accomplished of a number of significant milestones during the past twelve months and do not believe that our current valuation is reflective of the true value of our assets,” said Frank Thomas, President and Chief Executive Officer. “Therefore, we have initiated a comprehensive process to evaluate other strategies that might better maximize the value of our assets and ultimately realize value for our shareholders.”

For the three months ended September 30, 2007, the Company posted a net loss of $7.8 million, or $0.18 per share, based on 42.6 million weighted average common shares outstanding. This compares with a net loss of $8.9 million, or $0.26 per share, for the same period in 2006, based on 34.3 million weighted average shares outstanding. The increase in common shares outstanding resulted primarily from the Company’s registered direct offering of 7.5 million shares in October 2006.

During the third quarter of 2007, product sales of ZYFLO® (zileuton tablets), the Company’s immediate-release formulation of zileuton, and twice-daily ZYFLO CRTM (zileuton) extended-release tablets totaled $3.1 million, compared with product sales of ZYFLO that totaled $1.9 million in the third quarter of 2006, an increase of 66 percent. Critical Therapeutics and Dey, L.P. (DEY), a subsidiary of Mylan Inc., launched ZYFLO CR in the U.S. on September 27, 2007 for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. Third quarter 2007 sales of ZYFLO CR included initial shipments to wholesalers of approximately 4,300 units, representing approximately $870,000 in revenue.

Cash and short-term investments totaled $34.0 million as of September 30, 2007, compared with $40.5 million at June 30, 2007 and $40.2 million at September 30, 2006. Net cash expenditures in the third quarter of 2007 were $6.4 million, compared with net cash expenditures of $12.0 million in the third quarter of 2006 and $5.5 million in the second quarter of 2007. As of September 30, 2007, the Company had 43.1 million common shares outstanding, excluding warrants and stock options.

Review of Business Strategy and Future Operations

The board of directors and management are seeking to maximize the value of the Company’s commercial organization and product development programs. Together, they are currently evaluating a range of strategic alternatives that could result in potential changes to the Company’s current business strategy and future operations. The alternatives could include one or more potential transactions, such as the sale or divestiture of certain assets of the Company, the merger or sale of the Company, or other strategic transactions. The Company has engaged Lazard to advise it in considering potential strategic alternatives. Pending any decision to change strategic direction, the Company is continuing its commercial and development activities in accordance with its existing business strategy with an increased focus on the Company’s cash position.

There can be no assurance that the evaluation of strategic alternatives will lead to a change in the Company's current business strategy or result in one or more transactions. The Company does not intend to comment on the status of its evaluation of strategic alternatives unless and until there are material developments. As a result of potential changes in the strategic direction of Critical Therapeutics, the Company does not have sufficient information at this time to estimate the impact these potential changes or future transactions may have upon the operations of the Company and therefore is withdrawing its previously provided financial guidance.

Recent Developments

Since the end of the second quarter of 2007, Critical Therapeutics:

• Began promoting ZYFLO CR in the U.S. together with its co-promotion partner, DEY. With a combined sales force of approximately 240 representatives, Critical Therapeutics and DEY are marketing ZYFLO CR to a targeted group of allergists, pulmonologists and primary care physicians. ZYFLO CR and ZYFLO are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
• Began promoting PerforomistTM (formoterol fumarate) Inhalation Solution, DEY’s product for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) on October 8, 2007.

Initiated three clinical studies:

1. In July 2007, Critical Therapeutics initiated a Phase IV clinical trial designed to evaluate the efficacy of ZYFLO CR as an add-on therapy in asthma patients whose symptoms are uncontrolled despite taking moderate doses of inhaled corticosteroids.

2. In October 2007, the Company initiated a Phase I clinical trial to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of an oral single dose of the R(+) isomer of zileuton in healthy subjects.

3. In October 2007, Critical Therapeutics initiated a Phase II clinical trial to assess the effect on pulmonary function, safety, tolerability and the pharmacokinetic profile of the injectable formulation of zileuton (zileuton injection).

Commenced enrollment of patients in the LEUKO study, a randomized, double-blind, placebo-controlled clinical trial designed to examine the safety and efficacy of ZYFLO, in addition to usual care, for the treatment of acute exacerbations of COPD in 520 patients requiring hospitalization. The LEUKO study is being sponsored and funded by the National Heart, Lung and Blood Institute, part of the National Institutes of Health.

Continued to execute on its publication strategy with the announcement of two peer-reviewed publications:

1. Data from a Phase III clinical trial that was conducted primarily to evaluate the efficacy of ZYFLO CR compared with placebo was published in the Annals of Allergy, Asthma & Immunology.

2. Data from a 12-month, open-label, safety surveillance study that was designed to evaluate the long-term safety of ZYFLO and establish appropriate monitoring guidelines for liver function testing (LFT) were published in the Drug Safety edition of the Official Journal of the International Society of Pharmacovigilance.

Financial Results for the Three Months Ended September 30, 2007 and 2006

Total revenue for the three months ended September 30, 2007 was $3.2 million, compared with $4.4 million for the same period in 2006.

Revenue for the third quarter of 2007 included:

• Sales of ZYFLO and ZYFLO CR that accounted for $3.1 million in revenue, or 97 percent of total revenue. This compares with revenue from sales of ZYFLO of $1.9 million, or 43 percent of total revenue, in the third quarter of 2006. The 66 percent increase in product revenue is primarily attributable to the recognition of $870,000 in net product sales from ZYFLO CR, which was launched on September 27, 2007, and an 11 percent increase in ZYFLO’s wholesale acquisition price compared to the corresponding period in 2006. Starting January 1, 2007, the Company began recognizing revenue from product sales when the product was shipped to third-parties, less an estimate of expected product returns. Prior to this change, the Company recognized revenue from product sales only when the product was dispensed through patient prescriptions.
• Collaboration and license revenue of $93,000 from Critical Therapeutics’ HMGB1 collaboration with MedImmune, Inc. and its license agreement with Innovative Metabolics, Inc. to develop medical device approaches to stimulating the vagus nerve. This compares with collaboration and license revenue of $2.5 million in the third quarter of 2006. The decrease is associated with a decline in collaboration revenue from MedImmune. The Company’s future collaboration and license revenue from the MedImmune, Beckman Coulter and Innovative Metabolics agreements will primarily be recognized in periods when milestones are achieved, as all of the up-front payments under these agreements have now been fully amortized or recorded.
• Total operating expenses for the three months ended September 30, 2007 totaled $11.4 million, compared with $13.8 million for the same period in 2006, a decrease of 18 percent.

Total operating expenses for the third quarter of 2007 included:

• Cost of products sold that totaled $1.2 million, compared with $267,000 in the third quarter of 2006. Costs of products sold in the third quarter of 2007 consisted of manufacturing, distribution and other costs related to ZYFLO and ZYFLO CR and royalties paid to Abbott and SkyePharma related to ZYFLO and ZYFLO CR, as well as reserves established for excess or obsolete inventory. The Company recorded $219,000 of inventory write-offs in the third quarter of 2007 and did not record any inventory write-offs in the third quarter of 2006. Gross margins from product sales were 61 percent in the third quarter of 2007, compared with 86 percent in the third quarter 2006. In addition to the inventory write-offs in the third quarter of 2007, the decrease in gross margins is primarily related to higher manufacturing costs for ZYFLO CR and additional royalty obligations to SkyePharma for use of its controlled-release technology in ZYFLO CR. The Company also granted certain launch incentives to wholesalers during the third quarter of 2007 that resulted in lower margins for ZYFLO CR.
• Research and development (R&D) expenses that decreased $2.8 million, or 42 percent, to $3.9 million, compared with $6.7 million in the third quarter of 2006. This decrease was primarily due to a reduction in the number of employees performing R&D functions and nonrecurring milestone payments that were made in the third quarter of 2006. These decreases were partially offset by additional clinical costs related to the ZYFLO CR Phase IV clinical trial initiated in July 2007.
• Sales and marketing expenses that totaled $3.6 million, compared with $3.9 million in the third quarter of 2006. The decrease was primarily associated with the 2006 reduction in the Company’s sales force, partially offset by promotional and other marketing expenses associated with the launch of ZYFLO CR and the Company’s marketing obligations under its co-promotion agreement with DEY.
  General and administrative (G&A) expenses that totaled $2.7 million, compared with $2.9 million in the third quarter of 2006. The decrease was primarily due to a reduction in the number of employees performing G&A functions.

Financial Results for the Nine Months Ended September 30, 2007 and 2006

Total revenue for the nine months ended September 30, 2007 was $10.1 million, compared with $10.2 million for the same period in 2006. Product sales of ZYFLO and ZYFLO CR accounted for $8.3 million of revenue during the first nine months of 2007, compared with $4.7 million of product sales for ZYFLO during the first nine months of 2006, an increase of 76 percent. Starting January 1, 2007, the Company began recognizing revenue from product sales when the product was shipped to third-parties, less an estimate of expected product returns. Prior to this change, the Company recognized revenue from product sales only when the product was dispensed through patient prescriptions.

Critical Therapeutics’ collaboration with MedImmune and its license agreements with Beckman Coulter and Innovative Metabolics accounted for $1.8 million in revenue during the first nine months of 2007, compared with $5.4 million from the MedImmune collaboration and the Beckman Coulter license agreement during the first nine months of 2006.

Total operating expenses for the nine months ended September 30, 2007 were $37.0 million, compared with $52.1 million for the same period in 2006, a decrease of 29 percent. The decrease was primarily due to a reduction in the number of employees and certain R&D programs.

Research & Development Update

Critical Therapeutics’ preclinical and clinical development programs continue to progress with the initiation of three clinical trials during the third quarter of 2007.

ZYFLO CR Phase IV Trial

In July 2007, the Company initiated a Phase IV clinical trial to evaluate ZYFLO CR as an add-on therapy in asthma patients to support sales and marketing efforts for ZYFLO CR. The randomized, double-blind, placebo-controlled trial involving 400 patients will assess the effect of ZYFLO CR on lung function, asthma control and symptomatic response in adults whose asthma is not effectively controlled with moderate doses of inhaled corticosteroids.

Zileuton Injection Phase II Trial

The Company plans to develop an injectable formulation of zileuton for adjunctive use in emergency room or urgent care settings for acute asthma patients. In October 2007, the Company initiated a Phase II clinical trial focused on assessing efficacy and identifying the optimal dose to be tested in Phase III clinical trials. A total of 36 patients with stable chronic asthma are scheduled to be enrolled in the randomized, multi-center, double-blind, three-period crossover trial.

R(+) Zileuton Phase I Trial

In October 2007, Critical Therapeutics initiated a Phase I clinical trial to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of an oral single dose of the R(+) isomer of zileuton. A total of 12 healthy subjects were enrolled in the randomized, open-label, single-center, two-period crossover trial. The Company believes that the successful development of the R(+) isomer could lead to potential dosing improvements for patients, an enhanced product profile for zileuton for the treatment of asthma and provide for possible development opportunities in other inflammatory diseases, including COPD and nasal polyps.

Alpha-7 Program

The Company’s alpha-7 nicotinic receptor program, which is directed at the discovery and development of novel small molecule drugs for the treatment of inflammation, has selected a lead compound that is currently in preclinical development. The Company believes that this innovative anti-inflammatory approach has the potential for broad applications in both acute and chronic inflammatory diseases. The Company expects to begin GLP toxicology studies in 2008 and submit an Investigational New Drug (IND) application in the second half of 2008.

HMGB1 Program

The Company is collaborating with MedImmune on the development of a human monoclonal antibody to the cytokine HMGB1. The collaboration has identified potential clinical candidates that have shown efficacy in pre-clinical models of arthritis and lupus. The joint development team expects its next step to be the selection of a clinical candidate for the development of HMGB1 antibodies for inflammatory diseases, such as sepsis, lupus or rheumatoid arthritis.

DAKSHIDIN CORPORATION (OTC: DKSC)
"Up 14.29% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DKSC.php

Dakshidin Corporation through its wholly owned subsidiary, RESTEC International Inc. produces the world's most powerful pumping windmill. Throughout the world, especially in developing countries, there is a dire need for water to fulfill basic human self-sufficiency demands. In most cases, the problem is not the lack of available water, but the cost and reliability of obtaining it. The RESTEC Windmill is the renewable, cost-effective and environmentally friendly solution for the world's water crisis.

DKSC News:

November 9 - Dakshidin to Sign Memorandum of Understanding With Bengbu Government

Dakshidin Corporation (OTC: DKSC) (www.dakshidin.com) and its wholly owned subsidiary, Restec International Inc., producers of world's most powerful pumping windmill, announced that its President and CEO, Mr. Nick Laroche, will travel to China today in order to sign a Memorandum of Understanding (MOU) with the Municipal Government of Bengbu in the Province of Anhui of the People's Republic of China. This MOU outlines the intended Joint Venture with Huasheng (Bengbu) Environmental Energy Development Ltd.

"Securing this Joint Venture with the Bengbu Government has significant opportunities for Dakshidin. This relationship will position Dakshidin as a prominent player in one of the most prime development areas of renewable energy and water resources in China. The partnership will further allow Dakshidin to efficiently move forward with the Green Village Venture in the province of Anhui, China, as mentioned in the November 6th, 2007 press release," stated Nick Laroche, President and CEO of Dakshidin Corporation.

Proficiency testing on the Restec Mark 10 windmill has been carried out at the Texas A&M University and the Alberta Department of Agriculture. Field tests within Mexico, China and Arizona have concluded that the Restec Mark 10 windmill produces more water at a lower cost than any other windmill tested.

The RESTEC Windmill is the world's best renewable, cost-effective and environmentally friendly solution for the world's water and energy crisis.

CHINA VOICE HOLDING (OTC: CHVC)
"Up 16.10% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CHVC.php

China Voice Holding Corp., through its subsidiaries, provides communications products and services in the People's Republic of China and the United States. It offers Voice over Internet and other telecommunication services, office automation, wireless broadband, unified messaging, hosted groupware, mobile, and other voice and data services. The company also provides infrastructure to support the marketing, sale, and fulfillment of Asian communication products and services in the U.S.; and a vehicle to distribute and deploy the U.S. telecommunication, wireless, and technology products in Asia. In addition, China Voice Holding offers discount calling cards and virtual calling cards that are used to call from the United States to other countries, as well as to call from other countries to the United States, or to call between countries outside the United States; and distributes and manufactures broadband products and services. It serves CLEC's, Internet service providers, IXC's, cable companies, and other communication service providers. The company is headquartered in Dallas, Texas.

CHVC News:

November 8 - China Voice Holding Corp. Added to MicrocapMoney.com Index

CHVC Retains 3 Accounting Firms to Complete U.S. and China Subsidiary Audits by Year-End, Furthering All Regulatory Requirements to Apply For NASDAQ or AMEX Listing

Heritage First Capital & Equity Research Group (HFC), a financial research & data publisher, announced the addition of China Voice Holding Corporation (OTC: CHVC) to their Microcap Money Index of select companies with under $500 million in market capitalization.

China Voice, a U.S. holding company with numerous subsidiaries operating in both the United States and/or China, is the only wireless, telecommunications and next-generation technology company listed under the MicrocapMoney.com Index designation at www.OTCMoney.com.

The sheer depth and quality of China Voice’s announced contract awards and acquisitions over the last 110 days have prompted index profile coverage at MicrocapMoney.com

With China Voice well into their 2008 fiscal year (beginning July 1st), the Company recently issued guidance for fiscal 2008, along with estimates for their 2009 and 2010 fiscal years (ending June 30th). The company believes that it can achieve total revenues of $158 million in fiscal 2008, $311 million in 2009 and $497 million in 2010, with net earnings of $15.4 million, $34.5 million and $60.4 million, respectively.

CHVC Financial Data and Projections are available at www.chvcinfo.com/chvcinfo_projections_20070913.pdf.

CHVC is in the process of becoming a fully reporting company under U.S. SEC regulations and has engaged auditors to prepare the necessary documents and reports by 12/31/07.

After the SEC has approved the company’s filings, CHVC stock will automatically be eligible to trade on the OTC Bulletin Board. China Voice anticipates that it will also be eligible to be listed on the NASDAQ or American Stock Exchange at that time as well.

View the CHVC Annual Report (ending 6/30/2007) here www.pinksheets.com/otciq/ajax/showFinancialReportById?id=11998.

A full profile and quote for China Voice Holding Corporation is instantly available at www.otcmoney.com/company8.php.

EMPIRE FILM GROUP (OTC: EFGU)
"Up 13.64% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/EFGU.php

Empire Film Group, Inc. ("EFG") is a new independent film finance, production, and distribution company led by a management team with over 20 years of experience in development, production, distribution, finance and marketing of feature films and television programming. The group has filmed in various locations worldwide including the United States, Canada, the Caribbean, Central and South America and Europe. The Company has the unique financing advantage of being able to receive Canadian subsidies, tax incentives, rebates and financing through its ability to produce Canadian Content film and television projects. Learn more about Empire Film Group by visiting www.empirefilmgroup.com.

EFGU News:

November 9 - Empire Film Group Retains AGORACOM Investor Relations

Empire Film Group (OTC: EFGU) ("Empire Film") (www.empirefilmgroup.com) announced it has retained the services of AGORACOM Investor Relations ("AGORACOM") (www.agoracom.com) to provide investor relations services.

The objective of this agreement is two-fold. First, to create effective communication between Empire Film, its shareholders and the investment community through AGORACOM's Internet based investor relations system. Effective immediately, a customized and monitored Empire Film IR HUB will allow both Empire Film and AGORACOM to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications. The IR HUB will also provide one-click access to all critical Empire Film IR information, as well as an executive audio address. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the Company that is free of spam, bashing, hyping and profanity.

Second, AGORACOM will be responsible for raising Empire Film awareness amongst retail investors for the purposes of attracting new and prospective shareholders. As an exclusive small-cap content provider to Yahoo Finance Canada, AOL Finance Canada and every BlackBerry device on the planet, AGORACOM will provide Tier-1 financial coverage of all meaningful Empire Film press releases.

AGORACOM will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.

Empire Film Group CEO, Dean Hamilton Bornstein, stated, "Empire Film believes the time has now come to communicate with shareholders and the investment community. The solution provided by AGORACOM fulfils our need to manage and execute an IR strategy in a cost efficient manner, while providing our management team with the ability to focus on executing the business plan. Our shareholders and Company will benefit greatly from near real-time communications, regularly planned updates and increased exposure."

For all future Empire Film investor relations needs, investors are asked to visit the Empire Film IR Hub at http://www.agoracom.com/IR/EmpireFilm where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors are able to e-mail all questions and correspondence to This email address is being protected from spam bots, you need Javascript enabled to view it where they can also request addition to the investor e-mail list to receive all future press releases and updates in real-time.

About AGORACOM Investor Relations Corp.

AGORACOM Investor Relations is North America's leading outsourced investor relations firm for small-cap companies. AGORACOM's exclusive IR HUB delivers two-way investor relations and communications that provides 100% transparency, accessibility, equality and near real-time communications for all shareholders and the investment community.

AGORACOM has specialized in small-cap investor relations since 1997 and is the exclusive provider of all small-cap content to Yahoo Finance Canada, The AOL Small Cap Channel and every Blackberry device on the planet.